Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456886 | 0.81 | LTA4H (0.53) | TAAR1KCNA3LTA4HHTR1BLMNA | |
| SCHEMBL863049 | 0.81 | TAAR1 (0.50) | TAAR1KCNA3LTA4HPLA2G2AHTR1B | |
| SCHEMBL8820096 | 0.78 | LTA4H (0.61) | TAAR1AOC3KCNA3LTA4HPLA2G2A | |
| SCHEMBL45031 | 0.77 | TAAR1 (0.46) | TAAR1KCNA3LTA4HPLA2G2AMAOA | |
| SCHEMBL16425203 | 0.76 | HTT (0.46) | TAAR1KCNA3LTA4HPLA2G2AHTR1B | |
| Anisole SCHEMBL27502886 | 0.74 | CA4 (0.58) | TAAR1KCNA3LTA4H | |
| SCHEMBL12890249 | 0.74 | LMNA (0.48) | TAAR1KCNA3LTA4HMAOAPTGS1 | |
| SCHEMBL6002603 | 0.73 | LTA4H (0.49) | TAAR1KCNA3LTA4HLMNASMN1; SMN2 | |
| SCHEMBL23506286 | 0.72 | SMN1; SMN2 (0.44) | TAAR1LTA4HMAOAPTGS1SMN1; SMN2 | |
| SCHEMBL11212212 | 0.72 | TAAR1 (0.47) | TAAR1AOC3KCNA3LTA4HPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258757-A1 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LOADING | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-09-14 | — | — | US | claimed |
| EP-1888651-B1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | AGENCY SCIENCE TECH & RES (SG) | 2014-07-30 | — | — | EP | claimed |
| EP-2544768-A1 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LAODING | Agency For Science, Technology And Research (SG) | 2013-01-16 | — | — | EP | claimed |
| US-20130004488-A1 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LOADING | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-01-03 | — | — | US | claimed |
| US-8138163-B2 | Aldehyde conjugated flavonoid preparations | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-03-20 | — | — | US | claimed |
| WO-2011112156-A1 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LAODING | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-09-15 | — | — | WO | claimed |
| US-20110135733-A1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2011-06-09 | — | — | US | claimed |
| US-7858080-B2 | Aldehyde conjugated flavonoid preparations | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-12-28 | — | — | US | claimed |
| EP-1888651-A1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | Agency for Science, Technology and Research (SG) | 2008-02-20 | — | — | EP | claimed |
| WO-2006124000-A1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-11-23 | — | — | WO | claimed |
| WO-2023013719-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-02-09 | — | — | WO | disclosed |
| EP-2214715-B1 | METHOD OF DELIVERING AN ANTI-CANCER AGENT TO A CELL | AGENCY SCIENCE TECH & RES (SG) | 2018-04-18 | — | — | EP | disclosed |
| US-20180015180-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2018-01-18 | — | — | US | disclosed |
| EP-2323693-B1 | DRUG CARRIERS | NITTO DENKO CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170258757-A1 | ANTI-CANCER AGENT DELIVERY VEHICLES CAPABLE OF IMPROVED LOADING | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-09-14 | — | — | US | disclosed |
| US-20100028416-A1 | DRUG CARRIERS | NITTO DENKO CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2009054813-A1 | METHOD OF DELIVERING AN ANTI-CANCER AGENT TO A CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-04-30 | — | — | WO | disclosed |
| US-20080102052-A1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH | 2008-05-01 | — | — | US | disclosed |
| EP-1888651-A1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | Agency for Science, Technology and Research (SG) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006124000-A1 | ALDEHYDE CONJUGATED FLAVONOID PREPARATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028416-A1 | DRUG CARRIERS | HDGF, FIBP, HAVCR2 | TAAR1 3081/4885AOC3 3550/4885KCNA3 4872/4885 |
| US-20180015180-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | SLC43A1, SLC7A5, DNPEP | TAAR1 2849/4885AOC3 3765/4885KCNA3 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.